Lanean...
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
PURPOSE: To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. METHODS: Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the I...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Clinical Oncology
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3753701/ https://ncbi.nlm.nih.gov/pubmed/23918944 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.8313 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|